Astellas looks to Vesicare as growth saviour
This article was originally published in Scrip
Executive Summary
Amid continued generic onslaught for its top product Prograf (tacrolimus) last fiscal year, Astellas is focusing on its main growth opportunities, particularly the overactive bladder therapy Vesicare (solifenacin).